Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

Background In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gastroesophageal junction (G/GEJ) cancer but did elicit...

Full description

Bibliographic Details
Main Authors: Kohei Shitara, Kei Muro, Razvan Cristescu, Michael Nebozhyn, Andrey Loboda, Hyun Cheol Chung, Wasat Mansoor, Mustafa Ozguroglu, Mario Mandala, Maria Di Bartolomeo, Christian Caglevic, Julie Kobie, Min-Hee Ryu, Z Alexander Cao, Tomasz Olesinski, Eray Goekkurt, Raymond S McDermott, Zev A Wainberg, Chie-Schin Shih
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/6/e006920.full

Internet

https://jitc.bmj.com/content/11/6/e006920.full

Similar Items